Clinical Policy: Brivaracetam (Briviact)
Reference Number: CP.PCH.26
Effective Date: 05.21.19
Last Review Date: 08.20
Line of Business: Commercial, HIM

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Brivaracetam (Briviact®) is an anticonvulsant.

FDA Approved Indication(s)
Briviact is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.

As the safety of Briviact injection in pediatric patients has not been established, Briviact injection is indicated for the treatment of partial-onset seizures only in adult patients (16 years of age and older).

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Briviact is medically necessary when the following criteria are met:

I. Initial Approval Criteria
A. Partial-Onset Seizure (must meet all):
   1. Diagnosis of partial-onset seizure;
   2. Age ≥ 4 years;
   3. Failure of two preferred agents* for partial-onset seizures (see Appendix B) unless all are contraindicated or clinically significant adverse effects are experienced;
      *May require prior authorization.
   4. If request is for intravenous (IV) Briviact, member meets both of the following (a and b):
      a. Age ≥ 16 years;
      b. Oral Briviact administration is temporarily not feasible (e.g., status epilepticus, reliance on gastrostomy tube, recent oral or neck surgery, esophageal condition or intraoral infection, myasthenia gravis or other neuromuscular condition);
   5. Dose does not exceed 200 mg per day.

Approval duration: 12 months (oral formulation); 1 month (IV formulation)
B. Other diagnoses/indications
1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial or HIM.PHAR.21 for health insurance marketplace.

II. Continued Therapy
A. Partial-Onset Seizure (must meet all):
   1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Briviact for a covered indication and has received this medication for at least 30 days;
   2. Member is responding positively to therapy;
   3. Dose does not exceed 200 mg per day;
   Approval duration: 12 months (oral formulation); 1 month (IV formulation)

B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   Approval duration: Duration of request or 6 months (whichever is less); or
   2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial or HIM.PHAR.21 for health insurance marketplace.

III. Diagnoses/Indications for which coverage is NOT authorized:
A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial or HIM.PHAR.21 for health insurance marketplace, or evidence of coverage documents.

IV. Appendices/General Information
Appendix A: Abbreviation/Acronym Key
FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.
### Preferred drugs for partial-onset seizures:
- carbamazepine (Carbatrol®, Equetro®, Tegretol®, Tegretol XR®)
- clonazepam (Klonopin®)
- ethosuximide (Zarontin®)
- gabapentin (Neurontin®)
- lamotrigine (Lamictal®, Lamictal® ODT)
- levetiracetam (Keppra®, Keppra XR®)
- oxcarbazepine (Trileptal®)
- phenobarbital
- phenytoin (Dilantin®, Dilantin Infatabs®, Phenytek®)
- Lyrica® (pregabalin)
- primidone (Mysoline®)
- tiagabine (Gabitril®)
- topiramate (Topamax®, Topamax® Sprinkle)
- valproate (Depakene®, Depacon, Depakote®, Depakote® ER)
- Vimpat® (lacosamide)
- zonisamide (Zonegran®)

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

### Appendix C: Contraindications/Boxed Warnings
- Contraindication(s): hypersensitivity to brivaracetam or any of the inactive ingredients in Briviact.
- Boxed warning(s): none reported.

### V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
</table>
| Monotherapy or adjunctive therapy | **Adults (age ≥ 16 years; oral or intravenous):**  
  - Recommended starting dosage:  
    - 50 mg BID (100 mg/day)  
  - Maintenance dosage:  
    - 25 mg to 100 mg BID (50 to 200 mg/day)  
    *(Based on individual tolerability, therapeutic response.)*  
| **Pediatrics (age 4 years to < 16 years; oral only):**  
  - Weight ≥ 50 kg  
    - Recommended starting dosage:  
      - 25 mg to 50 mg BID (50 mg to 100 mg/day)  
    - Maintenance dosage:  
      - 25 mg to 100 mg BID (50 to 200 mg/day)  
      *(Based on individual tolerability, therapeutic response.)*  
  - Weight 20 kg to < 50 kg | 200 mg/day |
### Indication

<table>
<thead>
<tr>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Recommended starting dosage:</td>
<td></td>
</tr>
<tr>
<td>o 0.5 mg/kg to 1 mg/kg BID (100 mg/day)</td>
<td></td>
</tr>
<tr>
<td>• Maintenance dosage:</td>
<td></td>
</tr>
<tr>
<td>o 0.5 mg/kg to 2 mg/kg BID (1 mg/kg to 4 mg/kg per day)</td>
<td>(Based on individual tolerability, therapeutic response.)</td>
</tr>
</tbody>
</table>

### Weight 11 kg to < 20 kg

<table>
<thead>
<tr>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Recommended starting dosage:</td>
<td></td>
</tr>
<tr>
<td>o 0.5 mg/kg to 1.25 mg/kg BID (1 mg/kg to 2.5 mg/kg per day)</td>
<td></td>
</tr>
<tr>
<td>• Maintenance dosage:</td>
<td></td>
</tr>
<tr>
<td>o 0.5 mg/kg to 2.5 mg/kg BID (1 mg/kg to 5 mg/kg per day)</td>
<td>(Based on individual tolerability, therapeutic response.)</td>
</tr>
</tbody>
</table>

### VI. Product Availability

- Tablets: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg
- Oral solution: 10 mg/mL (300 mL)
- Injection: 50 mg/5mL (5 mL)

### VII. References

**Coding Implications**
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C9399, J3490</td>
<td>Injection, brivaracetam</td>
</tr>
</tbody>
</table>

**Reviews, Revisions, and Approvals**

<table>
<thead>
<tr>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>05.21.19</td>
<td>08.19</td>
</tr>
<tr>
<td>05.04.20</td>
<td>08.20</td>
</tr>
</tbody>
</table>

### Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan